Compare TCX & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | MXCT |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 136.0M |
| IPO Year | 2005 | 2021 |
| Metric | TCX | MXCT |
|---|---|---|
| Price | $8.58 | $1.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 66.9K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $362,275,000.00 | $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $8.92 | $0.64 |
| 52 Week High | $25.17 | $2.31 |
| Indicator | TCX | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 21.97 | 38.61 |
| Support Level | N/A | $1.08 |
| Resistance Level | $18.47 | $1.16 |
| Average True Range (ATR) | 0.83 | 0.09 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 5.42 | 6.10 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. The company generates key revenue from Canada and USA.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.